Mammalian Development and Manufacturing

Pre-clinical to Clinical

Lonza's UK facility is in the industrial town of Slough, located 22 miles west of central London.  Slough is a 65,000 square foot, multi-product cGMP manufacturing and development facility for Mammalian Biopharmaceuticals. The facility is focused on the manufacture of therapeutic grade monoclonal antibodies and recombinant proteins, using small to mid-scale fed-batch suspension culture of mammalian cell cultures. Lonza Slough was first multi-product licensed contract manufacturing facility to be licensed by the FDA, with its original Establishment License for the production of monoclonal antibodies first granted in 1985. Since then, regular inspections by the FDA and Europe’s MHRA have been hosted for both monoclonal antibodies and recombinant proteins.

The cGMP facility houses cell banking, production (fermentation and purification) and quality control laboratories. Contained within the two fermenter halls are numerous air lift and stirred-tank bioreactors with a wide range of manufacturing capacities (up to 2,000 Liters) able to handle pre-clinical and early clinical supply. Disposable, single-use bioreactors (SUBs) are also available. Each reactor has associated inoculum suites, media preparation areas and primary recovery equipment (comprising continuous centrifuge for cell removal, depth filtration, concentration and 0.2μm filtration equipment).

Capacity:

  • 1 x 200L (Airlift)
  • 1 x 800L (Stirred)
  • 3 x 1,000L (Single-use)
  • 1 x 2,000L (Airlift)
  • Associated Purification Suites
  • Process R&D Services